Omalizumab treatment in asthma-COPD overlap syndrome
JOURNAL OF ASTHMA, cilt.53, sa.10, ss.1048-1050, 2016 (SCI-Expanded)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 53 Sayı: 10
- Basım Tarihi: 2016
- Doi Numarası: 10.1080/02770903.2016.1178281
- Dergi Adı: JOURNAL OF ASTHMA
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1048-1050
- Anahtar Kelimeler: ACOS, omalizumab, LONG-TERM CONTROL
- Akdeniz Üniversitesi Adresli: Evet
Özet
Introduction: Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is a poorly understood disease with an increasing morbidity and mortality. Currently, the most effective treatment for ACOS is unknown and omalizumab for ACOS has not yet been reported. Methods: We report our experience with anti-IgE, omalizumab treatment on 3 patients with ACOS as a retrospective case study. Results: After 1 year of omalizumab treatment, patients experienced significantly lower rates of asthma exacerbation and hospitalization and better asthma control test results. Conclusion: Our study shows that omalizumab may be an effective and safe therapy for patients with ACOS. However larger randomized trials are needed.